Bli medlem
Bli medlem

Du är här

2015-05-28

Ablynx: ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE

GHENT, Belgium, 28 May 2015
-Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announces it will present at the Annual Jefferies 2015 Global Healthcare
Conference in New York City on Thursday, 4 June 2015 at09:30 a.m. EST (03:30
p.m. CET).

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO of
Ablynx. The presentation will provide an update on the Company's proprietary
key clinical assets, its partnered programmes and the outlook for the near
term future.

The presentation will be webcast live and can be accessed on the day via
thislink. A replay of the webcast will be available on the Company's website,
under thenews&eventssection, for 90 days following the presentation. To
ensure a timely connection, it is recommended that users register at least 10
minutes prior to the scheduled webcast.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has more than30 proprietary and partnered programmesin development in various
therapeutic areas including inflammation, haematology, immuno-oncology,
oncology and respiratory disease. The Company has collaborations with
multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim,
Eddingpharm, Genzyme, Merck&Co, Inc., Merck Serono and Novartis. The Company
is headquartered in Ghent, Belgium. More information can be found
onwww.ablynx.com.

For more information, please contact Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville
t: +44 203 709 5700
e:ablynx@consilium-comms.com

pdf format of the press release
http://hugin.info/137912/R/1924298/690218.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1924298

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.